Clinical Trial: Phase 1b Study to Investigate ABBV-CLS-7262's Safety, Tolerability & Pharmacokinetics in Vanishing White Matter Patients
Study Status: Completed
Recruit Status: RECRUITING
Condition: Vanishing White Matter Disease
Study Type: INTERVENTIONAL
Official Title: A Phase 1b Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following ABBV-CLS-7262 Administration in Adult Subjects With Vanishing White Matter Disease
Brief Summary:
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing White Matter disease.This is a 96-week, open-label, single arm study.Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.
Read more